Penumbra Inc. (PEN)

Penumbra, Inc. (NYSE:PEN ) Q2 2025 Earnings Conference Call July 29, 2025 4:30 PM ET Company Participants Adam Elsesser - Co-Founder, Chairman, President & CEO Cecilia Furlong - Corporate Participant ...

The headline numbers for Penumbra (PEN) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates...

Penumbra (PEN) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.64 per share a year ago.

Investors looking for stocks in the Medical - Instruments sector might want to consider either Integer (ITGR) or Penumbra (PEN). But which of these two stocks is more attractive to value investors?

Penumbra (PEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Penumbra (PEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Investors with an interest in Medical - Instruments stocks have likely encountered both Integer (ITGR) and Penumbra (PEN). But which of these two companies is the best option for those looking for und...

Penumbra's AI-guided aspiration system and scalable platform uniquely position it as a leader in stroke and PE intervention, justifying a Buy rating. First-mover advantage in intelligent thrombectomy,...

Zacks names PEN, ITGR and ANGO as medical device stocks riding genAI advances, despite global and inflationary headwinds.

Penumbra launches FDA-cleared Ruby XL System to bring advanced coil technology to high-flow embolization procedures.